Will the New Pharmacy Rules Revolutionize Medical Cannabis in Spain?

A historic regulatory green light allows Curaleaf to become the first company to register standardized treatments for Spanish hospital patients.

The landscape of healthcare in Southern Europe is experiencing a historic shift. The Spanish Agency of Medicines and Medical Devices (AEMPS) has officially approved the registration of two standardized medical cannabis preparations. This critical milestone represents the first time such registrations have been granted under the nation's new legislative framework, Royal Decree 903/2025. For millions monitoring global health developments, the rise of medical cannabis in Spain has officially transitioned from a policy debate into a concrete, pharmacy-ready reality. Observers at CIO Bulletin highlight that this landmark approval establishes a highly regulated pathway to distribute standardized therapies directly to those in clinical need.

"Spain, a country of nearly 50 million people, has always been central to Curaleaf's vision for Europe, and this registration is a defining moment for us."- Boris Jordan, Chairman and CEO, Curaleaf.

From Laboratories to Hospital Pharmacies

Under the newly minted Spanish national guidelines, the registered preparations, consisting of one THC-dominant formulation and one CBD-dominant formulation, will be distributed straight to hospital pharmacies. Specialist physicians can then prescribe these as customized, magistral formulas tailored to individual patient requirements.

The regulatory breakthrough introduces several key changes:

• Guaranteed Standardization: Patients receive precise, consistent doses, resolving the traditional clinical concern of variable cannabinoid levels.

• Hospital-Only Distribution: By restricting access to hospital settings, Spain ensures strict medical oversight and prevents diversion to the illicit market.

• A High-Growth Market: With a population of nearly 50 million, Spain is poised to become one of the most significant and standardized medicinal markets in Europe.

The foundation for this revolutionary decision has been built many years back at Curaleaf's laboratory based out of Alicante, where it has been carrying out high-level scientific research all along. With Europe heading towards pharmaceutical-grade oral solutions being heavily regulated, Spain has provided an impressive template to its neighbors.